Targeting Neuroimmune Interactions in Diabetic Neuropathy with Nanomedicine
Antioxidants & redox signaling
diabetes, diabetic neuropathy, nanomedicine, neuroimmune interaction, neuropathy, pain
Diabetes is a major source of neuropathy and neuropathic pain that is set to continue growing in prevalence. Diabetic peripheral neuropathy (DPN) and pain associated with diabetes are not adequately managed by current treatment regimens. Perhaps the greatest difficulty in treating DPN is the complex pathophysiology, which involves aspects of metabolic disruption and neurotrophic deficits, along with neuroimmune interactions. There is, therefore, an urgent need to pursue novel therapeutic options targeting the key cellular and molecular players. To that end, cellular targeting becomes an increasingly compelling drug delivery option as our knowledge of neuroimmune interactions continues to mount. These nanomedicine-based approaches afford a potentially unparalleled specificity and longevity of drug targeting, using novel or established compounds, all while minimizing off-target effects. The DPN therapeutics directly targeted at the nervous system make up the bulk of currently available treatment options. However, there are significant opportunities based on the targeting of non-neuronal cells and neuroimmune interactions in DPN. Nanomedicine-based agents represent an exciting opportunity for the treatment of DPN with the goals of improving the efficacy and safety profile of analgesia, as well as restoring peripheral neuroregenerative capacity. 36, 122-143.
Balogh, M., Janjic, J. M., & Shepherd, A. J. (2022). Targeting Neuroimmune Interactions in Diabetic Neuropathy with Nanomedicine. Antioxidants & redox signaling, 36 (2022-01-03), 122-143. https://doi.org/10.1089/ars.2021.0123